ResMed Inc. — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $1.42B | ↑+11.0% | $393M | ↑+13.9% | 34.6% |
| 2025-09-30 | $1.34B | ↑+9.1% | $349M | ↑+11.9% | 33.4% |
| 2025-06-30 | $1.35B | ↑+10.2% | $380M | ↑+29.9% | 33.7% |
| 2025-03-31 | $1.29B | ↑+7.9% | $365M | ↑+21.5% | 33.0% |
| 2024-12-31 | $1.28B | ↑+10.3% | $345M | ↑+65.0% | 32.5% |
| 2024-09-30 | $1.22B | ↑+11.1% | $311M | ↑+41.9% | 31.6% |
| 2024-06-30 | $1.22B | ↑+9.0% | $292M | ↑+27.2% | 31.2% |
| 2024-03-31 | $1.20B | ↑+7.2% | $300M | ↑+29.2% | 31.3% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Margin trends · 66 quarters
margin trajectory tells the operating-leverage storyGo deeper
RMD Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyRMD Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics